Sugi Predict

Sugi Predict / Compounds / SCHEMBL6048312

SCHEMBL6048312

SCHEMBL6048312

Brc1ccc(-c2ccccc2Oc2ccccc2-c2ccc(Br)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.48
▸ MAPK1 P28482 4/20 0.48
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ SLC6A3 Q01959 2/20 0.44
▸ PTGS2 P35354 1/20 0.43
▸ NPC1 O15118 4/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ TP53 P04637 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ PTPRC P08575 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ TSHR P16473 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ XDH P47989 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6269384 0.88 PTGS2 (0.58) ALDH1A1MAPK1NCOA1NCOA3SLC6A3
SCHEMBL11578092 0.86 PTGS2 (0.53) ALDH1A1SLC6A3PTGS2SMN1; SMN2PTPRC
SCHEMBL419231 0.83 NPC1 (0.59) ALDH1A1MAPK1SLC6A3NPC1RAB9A
SCHEMBL2059488 0.81 NCOA1 (0.59) ALDH1A1MAPK1NCOA1NCOA3PTGS2
SCHEMBL112422 0.80 NCOA1 (0.63) ALDH1A1MAPK1NCOA1NCOA3PTGS2
SCHEMBL19125933 0.80 ALDH1A1 (0.63) ALDH1A1MAPK1SLC6A3NPC1RAB9A
SCHEMBL7522172 0.80 ALDH1A1 (0.63) ALDH1A1MAPK1SLC6A3NPC1RAB9A
SCHEMBL28399794 0.79 ALDH1A1 (0.37) ALDH1A1MAPK1SLC6A3NPC1RAB9A
SCHEMBL17599648 0.79 SLC6A4 (0.47) ALDH1A1NCOA1NCOA3SLC6A3PTGS2
SCHEMBL11310044 0.78 MAPK1 (0.58) ALDH1A1MAPK1NCOA1NCOA3PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019118982-A1 MICROBE COMBINATIONS FOR BIOREMEDIATION AND METHODS OF USING THE SAME BIO-CAT MICROBIALS LLC (US) 2019-06-20 — — WO claimed
CN-105859728-B A kind of preparation method that Buddhist nun is replaced according to Shandong 江苏中邦制药有限公司 2018-06-08 — — CN claimed
CN-105859728-A Preparation method for ibrutinib 江苏中邦制药有限公司 2016-08-17 — — CN claimed
US-20060281961-A1 Functional transition metal silicates KANUMURU RAHUL RAJU (IN) 2006-12-14 — — US claimed
CN-114085207-B Bruton tyrosine protein kinase inhibitor and application thereof 广州百霆医药科技有限公司 2024-06-25 — — CN disclosed
CN-115078601-A Method for rapidly and synchronously extracting and measuring semi-volatile organic compounds and petroleum hydrocarbons in soil 新疆水清清环境监测技术服务有限公司 2022-09-20 — — CN disclosed
CN-114085207-A Bruton tyrosine protein kinase inhibitor and application thereof 广州百霆医药科技有限公司 2022-02-25 — — CN disclosed
WO-2019118982-A1 MICROBE COMBINATIONS FOR BIOREMEDIATION AND METHODS OF USING THE SAME BIO-CAT MICROBIALS LLC (US) 2019-06-20 — — WO disclosed
US-10023542-B2 Ibrutinib intermediate compounds, preparation methods and uses thereof Zhejiang Jiuzhou Pharmaceuticals Co., Ltd (CN) 2018-07-17 — — US disclosed
CN-105859728-B A kind of preparation method that Buddhist nun is replaced according to Shandong 江苏中邦制药有限公司 2018-06-08 — — CN disclosed
CN-106884224-A A kind of PET/PBT blending and modifyings fiber 福建经纬新纤科技实业有限公司 2017-06-23 — — CN disclosed
US-20170137386-A1 IBRUTINIB INTERMEDIATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF ZHEJIANG JIUZHOU PHARMA SCIENCE & TECHNOLOGY CO., LTD. (CN) 2017-05-18 — — US disclosed
EP-0033707-B1 ELEMENT FOR LIQUID ANALYSIS HAVING INTERFERENT-REMOVAL ZONE AND METHOD FOR USING SAME EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-06-20 — — EP disclosed
US-4303408-A EXTRACTION ZONE BEFORE INDICATOR ZONE EASTMAN KODAK COMPANY (US) 1981-12-01 — — US disclosed
EP-0033707-A1 Element for liquid analysis having interferent-removal zone and method for using same EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1981-08-12 — — EP disclosed
US-4175138-A α-Alkyl-p-phenoxy benzyl alcohols, compositions and treating lipidemia SANDOZ, INC. (US) 1979-11-20 — — US disclosed
US-4065503-A HYPOLIPIDEMIC AGENTS SANDOZ, INC. (US) 1977-12-27 — — US disclosed
US-3997567-A HYPOLIPIDEMIC SANDOZ, INC. (US) 1976-12-14 — — US disclosed
US-3962459-A Lipidemia treatment with p-phenoxy-alkylphenone compositions SANDOZ, INC. (US) 1976-06-08 — — US disclosed
US-3946119-A Optionally substituted α-tertiary butyl-p-phenoxybenzylamines and their use as hypolipidemic agents SANDOZ, INC. (US) 1976-03-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023542-B2 Ibrutinib intermediate compounds, preparation methods and uses thereof BTK, BCL6B, BCL6 ALDH1A1 1271/4885MAPK1 641/4885NCOA1 2959/4885
US-20170137386-A1 IBRUTINIB INTERMEDIATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF BTK, BCL6B, BCL6 ALDH1A1 1271/4885MAPK1 641/4885NCOA1 2959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.